DBV Technologies files BLA for peanut patch as going-concern doubt looms
DBV Technologies filed its Biologics License Application with the US FDA on 29 September 2026 for its VIASKIN Peanut Patch in children aged four through seven years, requesting Priority Review. The submission marks the French-American biotech's most significant regulatory step since pivoting away from an earlier, failed development pathway, and brings its epicutaneous immunotherapy (EPIT) platform to the edge of a potential US commercial launch.
The BLA is underpinned by the Phase 3 VITESSE trial, which enrolled 654 children and is described by the company as the largest immunotherapy trial to date in that age group. DBV has not yet published the full dataset; an FDA decision on whether to accept the dossier for substantive review, and on whether Priority Review is granted, is expected before the end of 2026.
Financial position and going-concern risk
DBV reported cash and cash equivalents of $165.7 million as of 30 September 2026, a position the company says funds operations into the third quarter of 2027. That runway, however, falls short of the twelve-month threshold required to avoid a going-concern disclosure under US accounting standards. Management has stated that substantial doubt exists about the company's ability to continue as a going concern within twelve months of the financial statements' issuance date.
Total operating expenses reached $66.3 million in the third quarter alone, up sharply from $37.1 million in the same period of 2025. The increase reflects a deliberate shift from clinical-stage spending toward commercial readiness: sales and marketing costs rose to $5.3 million in Q3 2026 from $1.2 million a year earlier, and G&A expenses nearly doubled to $14.0 million. Net loss for the quarter was $64.5 million, compared with $33.2 million in Q3 2025. Over the first nine months of 2026, the company burned through $159.4 million in operating and investing cash, against $86.7 million in the comparable 2025 period.
To bridge the funding gap, DBV completed a $50 million sale of American Depositary Shares to RA Capital Management and refreshed its $150 million at-the-market programme in the quarter. Management is evaluating additional equity, warrant and alternative financing structures, though the company cautions that no assurance exists that capital will be available on acceptable terms.
Toddler programme and competitive landscape
Beyond the 4-through-7 filing, DBV is advancing a second BLA for toddlers aged one through three years, with submission targeted for 2027. The FDA has indicated it would prefer a sequential review structure, allowing the same review team to build on learnings from the older-children dossier before assessing the toddler package. DBV characterises the content overlap between the two submissions as meaningful, which may compress the overall review timeline.
Chief executive Daniel Tassé said the company had "every function across the company aligned on supporting a complete and efficient review of both dossiers." DBV is also managing a complicating factor: an FDA Warning Letter issued in April 2026 to its contract manufacturer, Fareva Amboise. Fareva has responded to the agency within regulatory timelines and is working against a remediation plan developed with external specialists. A target date for the Pre-Approval Inspection has been included in the BLA, set to fall after Fareva's expected remediation completion.
The peanut allergy market has grown considerably more competitive since DBV's original regulatory setback. Palforzia, the oral immunotherapy from Nestle Health Science, remains the only approved treatment for peanut allergy in children, but a number of companies are pursuing sublingual, oral and epicutaneous approaches in overlapping age groups. EPIT's non-invasive profile is a meaningful differentiator for younger patients and their carers, where adherence to daily oral regimens can be challenging. FDA acceptance and Priority Review designation would provide a significant near-term catalyst, though investors will weigh that against the going-concern qualifier and the manufacturing overhang at Fareva.